Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: Fluorescent in situ hybridization analysis of 84 consecutive cases

Andrea L. Wiens, Liang Cheng, Elizabeth C. Bertsch, Karen A. Johnson, Shaobo Zhang, Eyas M. Hattab

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

It is well established that the combined del(1)(p36) and del(19)(q13) is a positive prognostic molecular event in oligodendroglial tumors. However, very little is known about the frequency or impact of polysomy status for chromosomes 1/19. We examined 84consecutive pure oligodendrogliomas (68 World Health Organization [WHO] grade II and 16 WHO grade III) and analyzed them for del(1)(p36) and del(19)(q13) by fluorescent in situ hybridization. Polysomy status was recorded with accompanying deletion status, WHO grade, recurrence-free survival, and overall survival. Codeletion of 1p/19q was detected in 48% of cases and correlated with superior patient survival (p < 0.01), as expected. Of 84 cases, 36 (43%) showed polysomy of chromosome 1, 30 (36%) demonstrated polysomy of chromosome 19, and 28 (33%) had copolysomies of chromosomes 1/19. The presence of polysomy of either/or both chromosomes, regardless of deletion status, correlated with younger patient age at initial diagnosis (p < 0.01). Combined polysomy was associated with higher histologic tumor grade (p = 0.04) and conferred poor survival likelihood (p = 0.03). We conclude that polysomy of 1 and/or 19 is a relatively frequent occurrence in oligodendrogliomas and usually confers an unfavorable outcome.

Original languageEnglish
Pages (from-to)618-624
Number of pages7
JournalJournal of Neuropathology and Experimental Neurology
Volume71
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Chromosomes, Human, Pair 19
Oligodendroglioma
Chromosomes, Human, Pair 1
Fluorescence In Situ Hybridization
Survival
Chromosome Deletion
Neoplasms
Recurrence

Keywords

  • Chromosome 1p/19q deletion
  • Fluorescent in situ hybridization
  • Molecular testing
  • Oligodendroglioma
  • Polysomy
  • Recurrence-free survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

@article{5cafcf0391a742479cc3fc7bb504b003,
title = "Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: Fluorescent in situ hybridization analysis of 84 consecutive cases",
abstract = "It is well established that the combined del(1)(p36) and del(19)(q13) is a positive prognostic molecular event in oligodendroglial tumors. However, very little is known about the frequency or impact of polysomy status for chromosomes 1/19. We examined 84consecutive pure oligodendrogliomas (68 World Health Organization [WHO] grade II and 16 WHO grade III) and analyzed them for del(1)(p36) and del(19)(q13) by fluorescent in situ hybridization. Polysomy status was recorded with accompanying deletion status, WHO grade, recurrence-free survival, and overall survival. Codeletion of 1p/19q was detected in 48{\%} of cases and correlated with superior patient survival (p < 0.01), as expected. Of 84 cases, 36 (43{\%}) showed polysomy of chromosome 1, 30 (36{\%}) demonstrated polysomy of chromosome 19, and 28 (33{\%}) had copolysomies of chromosomes 1/19. The presence of polysomy of either/or both chromosomes, regardless of deletion status, correlated with younger patient age at initial diagnosis (p < 0.01). Combined polysomy was associated with higher histologic tumor grade (p = 0.04) and conferred poor survival likelihood (p = 0.03). We conclude that polysomy of 1 and/or 19 is a relatively frequent occurrence in oligodendrogliomas and usually confers an unfavorable outcome.",
keywords = "Chromosome 1p/19q deletion, Fluorescent in situ hybridization, Molecular testing, Oligodendroglioma, Polysomy, Recurrence-free survival",
author = "Wiens, {Andrea L.} and Liang Cheng and Bertsch, {Elizabeth C.} and Johnson, {Karen A.} and Shaobo Zhang and Hattab, {Eyas M.}",
year = "2012",
month = "7",
doi = "10.1097/NEN.0b013e31825b5f7a",
language = "English",
volume = "71",
pages = "618--624",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas

T2 - Fluorescent in situ hybridization analysis of 84 consecutive cases

AU - Wiens, Andrea L.

AU - Cheng, Liang

AU - Bertsch, Elizabeth C.

AU - Johnson, Karen A.

AU - Zhang, Shaobo

AU - Hattab, Eyas M.

PY - 2012/7

Y1 - 2012/7

N2 - It is well established that the combined del(1)(p36) and del(19)(q13) is a positive prognostic molecular event in oligodendroglial tumors. However, very little is known about the frequency or impact of polysomy status for chromosomes 1/19. We examined 84consecutive pure oligodendrogliomas (68 World Health Organization [WHO] grade II and 16 WHO grade III) and analyzed them for del(1)(p36) and del(19)(q13) by fluorescent in situ hybridization. Polysomy status was recorded with accompanying deletion status, WHO grade, recurrence-free survival, and overall survival. Codeletion of 1p/19q was detected in 48% of cases and correlated with superior patient survival (p < 0.01), as expected. Of 84 cases, 36 (43%) showed polysomy of chromosome 1, 30 (36%) demonstrated polysomy of chromosome 19, and 28 (33%) had copolysomies of chromosomes 1/19. The presence of polysomy of either/or both chromosomes, regardless of deletion status, correlated with younger patient age at initial diagnosis (p < 0.01). Combined polysomy was associated with higher histologic tumor grade (p = 0.04) and conferred poor survival likelihood (p = 0.03). We conclude that polysomy of 1 and/or 19 is a relatively frequent occurrence in oligodendrogliomas and usually confers an unfavorable outcome.

AB - It is well established that the combined del(1)(p36) and del(19)(q13) is a positive prognostic molecular event in oligodendroglial tumors. However, very little is known about the frequency or impact of polysomy status for chromosomes 1/19. We examined 84consecutive pure oligodendrogliomas (68 World Health Organization [WHO] grade II and 16 WHO grade III) and analyzed them for del(1)(p36) and del(19)(q13) by fluorescent in situ hybridization. Polysomy status was recorded with accompanying deletion status, WHO grade, recurrence-free survival, and overall survival. Codeletion of 1p/19q was detected in 48% of cases and correlated with superior patient survival (p < 0.01), as expected. Of 84 cases, 36 (43%) showed polysomy of chromosome 1, 30 (36%) demonstrated polysomy of chromosome 19, and 28 (33%) had copolysomies of chromosomes 1/19. The presence of polysomy of either/or both chromosomes, regardless of deletion status, correlated with younger patient age at initial diagnosis (p < 0.01). Combined polysomy was associated with higher histologic tumor grade (p = 0.04) and conferred poor survival likelihood (p = 0.03). We conclude that polysomy of 1 and/or 19 is a relatively frequent occurrence in oligodendrogliomas and usually confers an unfavorable outcome.

KW - Chromosome 1p/19q deletion

KW - Fluorescent in situ hybridization

KW - Molecular testing

KW - Oligodendroglioma

KW - Polysomy

KW - Recurrence-free survival

UR - http://www.scopus.com/inward/record.url?scp=84862850802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862850802&partnerID=8YFLogxK

U2 - 10.1097/NEN.0b013e31825b5f7a

DO - 10.1097/NEN.0b013e31825b5f7a

M3 - Article

C2 - 22710961

AN - SCOPUS:84862850802

VL - 71

SP - 618

EP - 624

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 7

ER -